

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

LISTING OF CLAIMS:

1-11. (cancelled)

12. (currently amended) ~~Use of HMG box binding molecules for the preparation of therapeutic agents for the treatment of a~~
method for treating vascular diseases related to endothelial
and smooth muscle cells proliferation, said method comprising
administering to a subject in need thereof the therapeutic
agent of claim 16.

13. (currently amended) ~~Use of HMG box binding molecules for the preparation of therapeutic agents for the treatment of vascular diseases related to endothelial and smooth muscle cells proliferation~~The method according to claim 12,
~~characterised in that~~wherein the vascular diseases are due to atherosclerosis and/or restenosis after blood vessels damage.

14. (currently amended) ~~Use of HMG box binding molecules for the preparation of therapeutic agents for the treatment of vascular diseases related to endothelial and smooth muscle cells proliferation~~The method according to claim 12,

~~characterised in that~~wherein the vascular diseases are due to atherosclerosis and/or restenosis after blood vessels damage, including those events that occur after coronary and/or carotid angioplasty, with or without stent positioning, angiographic surgery, and surgery using catheters.

15. **(currently amended)** ~~Use of HMG box binding molecules~~The method according to claim 12, wherein said HMG box binding molecules belong to~~one~~molecule is chosen from the group comprising antibodies or antibodies fragments, inhibitors and four-way DNA.

16. **(currently amended)** ~~Therapeutic~~A therapeutic agent for the treatment of vascular diseases related to smooth muscle and endothelial cells proliferation~~characterised in that it comprises,~~ said agent comprising a therapeutic active amount of a HMG box binding molecules~~molecule~~.

17. **(currently amended)** ~~Therapeutic~~The therapeutic agent for the treatment of vascular diseases related to smooth muscle and endothelial cells proliferation according to claim 16, wherein said ~~molecules belong to the group comprising~~ HMG box binding molecule is chosen from antibodies or antibodies fragments, inhibitors and four-way DNA and not sRAGE.

18. **(currently amended)** ~~Therapeutic~~—The therapeutic agent for the treatment of vascular diseases related to smooth muscle and endothelial cells proliferation—~~characterised in that it comprises,~~ said agent comprising a therapeutic active amount of antagonist molecules having sequence homology with HMG box and being able to bind ~~the~~ a functional HMG box binding domain of the receptor.

19. **(currently amended)** ~~Therapeutic~~—The therapeutic agent according to claim 16, ~~characterised in that it~~ wherein said agent is released by catheters, surgical instruments implants or stents.